IXICO to show off experimental tech to global pharma firms

Brain health company IXICO announced on Friday that its executive director Professor Derek Hill was set to present the firm’s experimental technology to measure sleep from wearable sensors at a mobile devices for clinical trials in neurological diseases workshop involving global pharmaceutical companies.

The AIM-traded company’s technology reportedly analyses sleep pattern data obtained from wrist-worn accelerometers.

It said its algorithm was developed using the artificial intelligence ‘deep learning’ technique utilising data from normal elderly patients, as well as patients with neurodegenerative diseases wearing an accelerometer at a sleep laboratory.

IXICO said sleep disturbance was a challenging symptom of many brain diseases, and could also be a side effect of new drug treatments.

The board explained that the ability to measure sleep accurately was therefore important for assessing both the benefits and side effects of new drugs under development for the treatment of serious diseases of the brain.

It said the mobile devices for clinical trials in neurological diseases workshop was jointly hosted by the Clinical Data Interchange Standards Consortium and the Critical Path Institute Coalition Against Major Diseases, and was addressing the data standards challenges in enabling mobile devices to meet the rigorous regulatory requirements of the FDA.

“We are pleased to showcase our innovative sleep measurement technologies at this prestigious workshop,” Professor Hill said.

“Engaging with organizations such as CAMD and CDISC in advancing data standards and addressing regulatory challenges enables IXICO to provide our customers and collaboration partners in the pharmaceutical industry with unique solutions to meet their rapidly growing need for digital technologies to support the bringing of new drugs to market.”